Transcriptomic and metabolite-centric profiling reveal aryl hydrocarbon receptor-mediated cytochrome P450 1A1 autoinduction of the selective modulator PM-4321
Drug developers identified an unexpected metabolism problem in their experimental therapy, refining how future compounds are designed and tested.
Flagship Pioneering researchers identified CYP1A1 autoinduction as the mechanism behind unexpected pharmacokinetic decline of their AhR modulator PM-4321, requiring integration of transcriptomics and metabolite profiling beyond standard DMPK workflows. This is a drug development DMPK finding with limited direct clinical relevance at this stage.
What the study was
- Study design
- Preclinical pharmacokinetic and transcriptomic study
- Population
- Preclinical species (mice, monkeys); in vitro hepatocyte assays
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Drug Metabolism and Disposition
Why it surfaced
Preclinical pharmacokinetic/DMPK study; limited direct clinical relevance; watchlist match is peripheral (cancer immunotherapy program).
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.